Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients

Lignende værker

• CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study
  af: Belogurov, Alexey, et al.
  Udgivet: (2016)
• Liposome-encapsulated peptides protect against experimental allergic encephalitis
  af: Belogurov, Alexey A., et al.
  Udgivet: (2013)
• Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity
  af: Belogurov, Alexey, et al.
  Udgivet: (2015)
• Divergent Immunomodulation Capacity of Individual Myelin Peptides—Components of Liposomal Therapeutic against Multiple Sclerosis
  af: Ivanova, Vilena V., et al.
  Udgivet: (2017)
• Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome
  af: Kuzina, Ekaterina, et al.
  Udgivet: (2014)